Nicoletta Bernardini

Latina, 04100, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 134 publications

Guselkumab Every 4 Weeks as a Real-World Therapeutic Option for Psoriatic Arthritis Patients at High Risk of Joint Damage.

Guselkumab Every 4 Weeks as a Real-World Therapeutic Option for Psoriatic Arthritis Patients at High Risk of Joint Damage.

Journal: Clinics and practice

Published: July 08, 2026

Real-life effectiveness and safety of bimekizumab in patients with moderate plaque psoriasis: a 54-week multicentre study in the Lazio region.

Real-life effectiveness and safety of bimekizumab in patients with moderate plaque psoriasis: a 54-week multicentre study in the Lazio region.

Journal: Drugs in context

Published: May 06, 2026

Effectiveness of Guselkumab for the Treatment of Moderate-to- Severe Psoriasis in Elderly Patients: A Retrospective, Real-World Multicenter Study in the Lazio Region.

Effectiveness of Guselkumab for the Treatment of Moderate-to- Severe Psoriasis in Elderly Patients: A Retrospective, Real-World Multicenter Study in the Lazio Region.

Journal: Clinics and practice

Published: April 29, 2026

Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis.

Beyond Psoriasis Area and Severity Index and Body Surface Area: An Italian Delphi Consensus on the Definition of Moderate Psoriasis.

Journal: Dermatology and therapy

Published: April 10, 2026

Comparing the clinical response and patient satisfaction of foam versus cream calcipotriol-betamethasone dipropionate treatment of localized plaque psoriasis.

Comparing the clinical response and patient satisfaction of foam versus cream calcipotriol-betamethasone dipropionate treatment of localized plaque psoriasis.

Journal: Italian journal of dermatology and venereology

Published: April 08, 2026

Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study.

Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study.

Journal: Journal of cutaneous medicine and surgery

Published: March 17, 2026

Survey on the management and patient satisfaction levels in individuals with psoriasis and/or psoriatic arthritis.

Survey on the management and patient satisfaction levels in individuals with psoriasis and/or psoriatic arthritis.

Journal: Dermatology reports

Published: December 21, 2025

Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the Legs.

Psoriasis in Difficult-to-Treat Areas: A Multicentre, Real-World Retrospective Study Analyzing the Impact of Non-Invasive Imaging Techniques (Dermoscopy, Reflectance Confocal Microscopy and Optical Coherence Tomography) to Monitor the Effectiveness of Risankizumab in the Treatment of Plaque Psoriasis of the Legs.

Journal: Clinics and practice

Published: November 19, 2025

Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index.

Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index.

Journal: The Journal of dermatological treatment

Published: September 24, 2025

Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms.

Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms.

Journal: Drugs in context

Published: May 06, 2025

Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre study.

Switching to brodalumab after failure of IL-17A inhibitors in psoriatic patients: A real-life multicentre study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 22, 2025

Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study.

Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study.

Journal: Psoriasis (Auckland, N.Z.)

Published: April 08, 2025

Showing 1-12 of 134

Last Updated: 09/26/2026